Global Bioengineered Skin Substitutes Market Growth (Status and Outlook) 2023-2029

Global Bioengineered Skin Substitutes Market Growth (Status and Outlook) 2023-2029

Bioengineered skin consists of the outer epidermis and/or dermis (the layer of skin between the epidermis and subcutaneous tissue) embedded in an acellular matrix (supporting structure) to form a biological skin substitute. Products are made from a variety of sources, including human tissue (from patients or others), non-human tissue (bovine, porcine, horse), synthetic materials (man-made), or a combination of these materials.

LPI (LP Information)' newest research report, the “Bioengineered Skin Substitutes Industry Forecast” looks at past sales and reviews total world Bioengineered Skin Substitutes sales in 2022, providing a comprehensive analysis by region and market sector of projected Bioengineered Skin Substitutes sales for 2023 through 2029. With Bioengineered Skin Substitutes sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bioengineered Skin Substitutes industry.

This Insight Report provides a comprehensive analysis of the global Bioengineered Skin Substitutes landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bioengineered Skin Substitutes portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bioengineered Skin Substitutes market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bioengineered Skin Substitutes and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bioengineered Skin Substitutes.

The global Bioengineered Skin Substitutes market size is projected to grow from US$ 1433.4 million in 2022 to US$ 3218.8 million in 2029; it is expected to grow at a CAGR of 12.3% from 2023 to 2029.

Global important companies in bioengineered skin substitutes includes Allergan (AbbVie), AlloSource, Organogenesis, and BD. The head company shares over 30% of the market. Geographically speaking, Americas holds about 50% of global market share, followed by Europe with about 35% share. Bioengineered skin substitutes includes Allogeneic Acellular, Xenogeneic, Allogeneic Cells, and Autologous. Allogeneic Acellular is the largest part of bioengineered skin substitutes industry, has a share about 80%. Other key parts include Xenogeneic who shares nearly 15% , and Autologous who shares about 5%. The application of bioengineered skin substitutes includes hospitals,specialty clinics and wound care centers. Hospitals shares the largest percent of 60.30%.

This report presents a comprehensive overview, market shares, and growth opportunities of Bioengineered Skin Substitutes market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Allogeneic Acellular
Xenogeneic
Allogeneic Cells
Autologous

Segmentation by application
Hospitals
Specialty Clinics
Wound Care Centers

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Allergan (AbbVie)
AlloSource
Organogenesis
BD
Smith & Nephew
Integra LifeSciences
Synthes (Johnson & Johnson)
Axogen
Vericel Corporation
LifeNet Health
MTF Biologics
Arthrex
Wright Medical Group NV (Stryker)
Cook Biotech Incorporated
Aroa Biosurgery
Surgalign Holdings
Anika Therapeutics
Forticell Bioscience
MLM Biologics
Promethean LifeSciences

Please note: The report will take approximately 2 business days to prepare and deliver.